The Biggest Surprises of 2006
This article was originally published in RPM Report
Executive Summary
When Wall Street analysts were asked to weigh in on the top events of 2006, they were right about many of their predictions. But there were a few that caught everyone off guard: the FDA approval prospects of Sandoz' follow-on human growth hormone Omnitrope and Sanofi-Aventis' weight loss drug rimonabant.